WKBT Weikang Bio-Technology Group Co., Inc. featured news, full reports, and detailed charts
Weikang Bio-Technology Group Co., Inc. (WKBT/WKBT.OB) Wrap Up:
Weikang Bio-Technology Group Company, Inc. engages in the research, development, manufacture, marketing, and sale of herbal-based health and nutritional supplements in the People’s Republic of China. It offers a series of health supplements under a Chinese trade name, which English transliteration is ‘Rongrun’. The ‘Rongrun’-line of products include youth keeping capsules, energy keeping capsules, vitamin sugar capsules, intestine cleansing capsules, artery cleansing capsules, royal jelly extract, and kidney boost tonic. The company is also developing 10-hydroxy-2-decylenic acid for the treatment of radiation damages and angiocardiopathy. It sells its products to wholesale dealers, retail st...Weikang Bio-Technology Group Co., Inc. (WKBT:OTC Bulletin Board Market)
Snapshot of Weikang Bio-Technology Group Co., Inc. (WKBT)
|
OPEN
$2.90
|
PREVIOUS CLOSE
$2.79
|
|
|
DAY HIGH
$3.12
|
DAY LOW
$2.70
|
|
|
52 WEEK HIGH
06/18/09 - $4.00
|
52 WEEK LOW
04/8/09 - $0.20
|
|
|
MARKET CAP
70.1M
|
AVERAGE VOLUME 3 mo
10.0K
|
|
|
DILUTED EPS TTM
$0.59
|
SHARES OUTSTANDING
25.5M
|
|
|
WKBT Does Not Pay Dividends
|
P/E TTM
4.6x
|
|
| K = Thousands M = Millions B = Billions | ||
WKBT Top Compensated Officers
Executives, Board Directors
Key developments for Weikang Bio-Technology Group Co., Inc. (WKBT)
On 11/16/2009, Weikang Bio-Technology Group Co., Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Weikang Bio-Technology Group Co. Inc. reported earnings results for the second quarter and six months ended June 30, 2009. Revenues were $13.20 million for the three months ended June 30, 2009 as compared to $2.05 million for the corresponding period in 2008 due to the June 30 acquisition of Tianfang (Guizhou) Pharmaceutical Co., Ltd, an OTC pharmaceuticals developer and manufacturer. Gross profit increased to $7.09 million, up 429% from $1.34 million for the same period last year. Net income was $3.33 million or $0.13 per fully diluted share, up 203% from $1.10 million for the same period year over year. For the six months ended June 30, 2009, total operating revenues were $23.31 million, up 628% from $3.20 million from the same period last year. Gross profit was $12.74 million, up 528% from the same period 2008. Net income increased by $5.53 million (333%) to $7.19 million for the six months ended June 30, 2009, as compared to the corresponding three and six month periods in 2008.
On 08/14/2009, Weikang Bio-Technology Group Co., Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
WKBT Competitors
| Company | Last | Change | |
| No competitor information is available for WKBT. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | WKBT | Industry Range |
| Price/Earnings | 5.4x |
|
| Price/Sales | 2.1x |
|
| Price/Book | 4.7x |
|
| Price/Cash Flow | 5.5x |
|
| TEV/Sales | 2.0x |
|
|
WKBT |
||
WKBT transactions
| Type Date |
Target |
|
Private Placement
August 11, 2009 |
-- |